Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1111/j.1469-8749.1973.tb05070.x | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Sturge Weber syndrome with intraoral manifestations. A case report.
Indian J Dent Res
November 1999
Department of Oral and Maxillofacial Surgery, Punjab Govt Dental College, Amritsar, India.
A 15 Year old female patient with Sturge Weber Syndrome is presented. This neurocutaneous syndrome consists of angiomatosis of the skin and mucosa as well as the leptomeninges. This case report describes the classic presentation of the syndrome, emphasizing the oral manifestations.
View Article and Find Full Text PDFIncreased glucocorticoid receptors in diphenylhydantoin induced human gingival overgrowth.
Biochem Int
July 1991
Department of Biochemistry, Central Leather Research Institute, Adyar, Madras, India.
A pilot study on the glucocorticoid receptors in normal and pathological condition of human gingiva was carried out for a better perception of glucocorticoid action in gingiva. Gingival cytosol prepared from normal and diphenylhydantoin induced overgrowth was incubated with [3H]dexamethasone with or without cold competitor. Results obtained show a single class of receptor in both the conditions with no difference in binding specificity.
View Article and Find Full Text PDFDiphenylhydantoin-induced gingival overgrowth in man: a clinico-pathological study.
J Periodontol
September 1990
Section of Oral Medicine, Faculty of Medicine and Dentistry, Valencia, Spain.
In a cross-sectional, epidemiological study of diphenylhydantoin-induced gingival overgrowth (DGO) in 60 epileptic patients, gingival lesion severity was statistically compared with other clinical, laboratory, and histopathological findings. Evident DGO was observed in 50% of patients, and positive correlations were detected between overgrowth severity and oral debris, calculus accumulation, plaque score, gingival inflammation, and probing depth. However, no valid correlation was observed between lesion and patient age, mouth breathing, daily drug dose, plasma diphenylhydantoin level, or duration of drug intake.
View Article and Find Full Text PDFDiphenylhydantoin, which was first introduced in clinic by Meritt and Putnam in 1938, has been in wide use for the treatment of epilepsy because of its excellent antispasmodic action. On the other hand, Diphenylhydantoin induced gingival hyperplasia has been examined by many authors in the dental field since gingival hyperplasia was reported by Kimball as its side effect. Recently, we had an opportunity for performing gingivectomy on hypertrophic gingivitis in an epileptic with mental retardation and visual disturbance, on Phenytoin (5,5-Diphenylhydantoin) medication.
View Article and Find Full Text PDFFolate treatment of diphenylhydantoin-induced gingival hyperplasia.
Scand J Dent Res
June 1989
Public Dental Health Service, County of Västerbotten, Umeå, Sweden.
It has recently been reported that folic acid supplementation reduced DPH-induced gingival hyperplasia in cat and in a pilot study also in man. The present study was performed to further evaluate this therapy in man. Twenty-three children with DPH-treatment for more than 1 yr, and eight children with short-time DPH-treatment were randomly assigned to groups with and without daily supplementation of folic acid (5 mg Folacin) for 1 yr.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!